Community Acquired Pneumonia: Comprehensive Evidence-Based Guide

1. Executive Summary

Community Acquired Pneumonia (CAP) is an acute infection of the lung parenchyma acquired outside of the hospital setting or within 48 hours of admission. [1] It remains a leading cause of infectious death globally, particularly in the elderly and those with significant comorbidities, with an estimated 5-11 cases per 1000 adults annually. [2] The pathophysiology involves a breakdown in host pulmonary defenses (mucociliary and macrophage failure) leading to the hallmark four stages of lobar hepatisation when caused by Streptococcus pneumoniae. [3,10]

Clinical severity is objectively stratified using the CURB-65 score (and increasingly the PSI/PORT score), which dictates the site of care and antibiotic intensity. [3,11] Modern management focuses on the "Golden Hour" for severe cases, early transition from IV to oral therapy (PIVOT trial), and limited duration (5 days) for uncomplicated cases to prevent antimicrobial resistance. [4,12] Mortality remains high in severe cases (up to 40% in CURB-65 score > 3), driven by septic shock and Type 1 respiratory failure. [1,5]

Recent advances include the recognition of viral-bacterial co-infection (particularly post-influenza and COVID-19), the evolving role of biomarkers (procalcitonin, C-reactive protein), and refinements in antibiotic stewardship. [13,14] Vaccination strategies (pneumococcal, influenza, COVID-19) remain the cornerstone of prevention, with PCV13 and PPSV23 reducing invasive disease by up to 75% in the elderly. [15]

2. Key Facts: High-Yield Exam Points

• The "Commonest" Killer: Streptococcus pneumoniae remains the most frequent bacterial cause (~30-50% of cases), though viral causes (Influenza, RSV, COVID-19) are increasingly recognized and often co-exist. [1,4,16]

• The 5-Day Mandate: For uncomplicated CAP meeting clinical stability criteria, a 5-day antibiotic course is non-inferior to longer courses (7-10 days) and reduces side effects and antimicrobial resistance. [2,12]

• Procalcitonin Utility: Procalcitonin should NOT be used to decide whether to start antibiotics in CAP but can safely guide early cessation in stable patients, reducing antibiotic exposure by 2-3 days. [1,17]

• The "Post-Obstructive" Rule: Any patient > 50 years or with a smoking history must have a follow-up CXR at 6 weeks to rule out underlying malignancy masking as pneumonia (2-5% incidence). [1,5]

• Macrolide Resistance: In regions with high S. pneumoniae macrolide resistance (> 25%), macrolide monotherapy should be avoided even in mild cases. Dual therapy with beta-lactam remains preferred. [4,18]

• The "Golden 4 Hours": Administration of antibiotics within 4 hours of arrival is associated with reduced mortality in hospitalized patients (NNT ~17 to prevent one death). [3,19]

• Failure to Improve: If clinical improvement has not occurred by 48-72 hours, consider complications (empyema, abscess), resistant organisms, incorrect diagnosis, or immunosuppression. [1,20]

• Radiological Lag: CXR changes lag behind clinical improvement by 6-12 weeks. Do not change antibiotics based on persistent radiological abnormalities if the patient is clinically improving. [21]

3. Clinical Pearls: Pattern Recognition

The "Hypotension" Warning: In young, healthy patients, hypotension is a pre-terminal sign of exhaustion. Unlike the elderly, they maintain blood pressure until they are near arrest. Any SBP less than 100 in a young CAP patient is an emergency. [1]

The "Silent" Elder: In patients > 80 years, cough and fever may be absent. New-onset confusion (delirium) is often the only presenting sign of severe pneumonia. This is due to immunosenescence and blunted inflammatory response. [22]

The "Rust" Sign: "Rusty" sputum is pathognomonic for S. pneumoniae and represents the "Red Hepatisation" phase where RBCs are leaking into the alveoli. However, it is only present in ~25% of cases. [10]

The "Legionella" Clue: Suspect Legionella if there is a "clinical-radiological dissociation" (patient looks much sicker than the CXR), hyponatraemia (Na less than 130 mmol/L), and diarrhoea. Also associated with recent travel, water exposure (air conditioning, hot tubs), and elevated LFTs. [23]

The "Double Pneumonia" Danger: Bilateral infiltrates in an immunosuppressed patient should raise suspicion for Pneumocystis jirovecii (PCP), fungal infection, or viral pneumonia. Urgent HIV testing and consideration of atypical coverage is mandatory. [24]

The "Effusion" Rule: Up to 40% of hospitalized CAP patients develop a parapneumonic effusion. If > 1cm on lateral decubitus CXR or ultrasound, it requires diagnostic thoracentesis to rule out empyema. [25]

4. Epidemiology: The Burden of Disease

Incidence and Prevalence

• Overall Incidence: 5-11 per 1000 adults per year in the UK and USA. [1,2]
• Age-Related Increase: Incidence increases exponentially with age, from 1-5 per 1000 in young adults to 25-44 per 1000 in those > 85 years. [2]
• Seasonal Variation: Bimodal peak in winter months (December-March in Northern Hemisphere), coinciding with viral respiratory season. Influenza co-infection increases bacterial CAP risk by 100-fold. [4,26]

Mortality and Morbidity

• Outpatient Mortality: less than 1-2% for those managed at home (CURB-65 0-1). [5,13]
• Hospitalized Ward Patients: 5-15% mortality. [5,13]
• ICU Admission: 25-50% mortality, depending on need for mechanical ventilation and vasopressors. [5,13]
• 30-Day Readmission: 15-20% of discharged patients are readmitted within 30 days, often for heart failure or recurrent infection. [27]
• Long-Term Outcomes: Survivors have increased risk of cardiovascular events (MI, stroke) in the year following CAP, possibly due to systemic inflammation. [28]

Risk Factors (Evidence-Based)

Microbiology: Evolving Landscape

Pre-COVID Era (2015-2019):

• Streptococcus pneumoniae: 30-50%
• Viral (Influenza, RSV, Rhinovirus): 15-30%
• Haemophilus influenzae: 5-10%
• Atypicals (Mycoplasma, Chlamydophila, Legionella): 10-20%
• Staphylococcus aureus: 3-5%
• Gram-negatives (Klebsiella, E. coli): 3-5%
• No pathogen identified: 30-50% [1,4]

Post-COVID Era (2020-2026):

• Viral CAP now accounts for up to 40-50% of cases.
• S. pneumoniae remains commonest bacterial cause, but proportionally less.
• Increased S. aureus CAP (including MRSA) post-influenza and post-COVID. [16,30]
• Rising antibiotic resistance: macrolide resistance in S. pneumoniae (15-40%), fluoroquinolone resistance emerging. [18]

5. Molecular Pathophysiology: The 7-Step Cascade

Step 1: Inoculation and Alveolar Entry

Bacteria reach the lower respiratory tract primarily through micro-aspiration of oropharyngeal flora during sleep (most common), inhalation of aerosolized droplets (e.g., Legionella), or less commonly via haematogenous spread from distant infection. [3,10] Micro-aspiration occurs in up to 45% of healthy individuals during sleep but does not cause infection due to intact host defenses. [10]

Step 2: Alveolar Macrophage Failure

The first line of defense, alveolar macrophages, attempt to phagocytose the invaders via pattern recognition receptors (TLRs). Pneumonia occurs when the inoculum size or virulence (e.g., Pneumococcal polysaccharide capsule that inhibits phagocytosis) overcomes macrophage capacity, triggering a massive inflammatory cascade via release of TNF-α, IL-1β, and IL-8. [10,30]

Step 3: Neutrophil Recruitment and Cytokine Storm

Chemokines (IL-8, C5a) recruit neutrophils from the bloodstream into the alveolar space. This is mediated by upregulation of adhesion molecules (ICAM-1, VCAM-1) on endothelium. Neutrophils release reactive oxygen species, myeloperoxidase, and neutrophil extracellular traps (NETs), which kill bacteria but also cause collateral damage to alveolar epithelium. [30]

Step 4: Stage 1 - Congestion (Day 1-2)

The lung becomes heavy, "boggy," and red. Histology shows vascular engorgement, intra-alveolar fluid (oedema) with many bacteria, and few neutrophils. This is the earliest phase of consolidation. Clinically, the patient has cough and fever, but physical signs may be minimal. [3,10]

Step 5: Stage 2 - Red Hepatisation (Day 3-4)

The alveoli fill with massive amounts of RBCs (due to capillary leakage), neutrophils, and fibrin. Macroscopically, the lung looks solid and "liver-like" (hence "hepatisation"). Clinical signs of consolidation (bronchial breathing, dullness to percussion, increased vocal resonance) are maximal here. The patient has high fever, pleuritic chest pain, and rusty sputum. [3,10]

Step 6: Stage 3 - Grey Hepatisation (Day 5-7)

RBCs disintegrate, while the fibrinopurulent exudate persists. The lung appears grey-brown and dry. This represents the peak of the immune response and the transition to healing. The patient may start to show clinical improvement (defervescence), but radiological changes persist. [10]

Step 7: Stage 4 - Resolution (Day 8+)

Macrophages return to the site to ingest debris and fibrin via efferocytosis. The architecture is ideally restored to normal (restitutio ad integrum). If resolution fails, the exudate may "organize," leading to permanent fibrosis (organizing pneumonia). [3,10]

Step 8: V/Q Shunting and Hypoxaemia (Physiology)

Filled alveoli cannot participate in gas exchange (V = 0), but blood flow continues (Q = Normal). This creates a right-to-left shunt, leading to Type 1 respiratory failure (hypoxaemia with normal or low PaCO2) that is often poorly responsive to simple oxygen therapy. Hypoxaemia is corrected only when the shunt resolves or high-flow oxygen is applied. [10,18]

Immunological Considerations

• Elderly: Immunosenescence leads to reduced neutrophil function, lower cytokine response, and impaired T-cell activation. This explains the "silent" presentation and higher mortality. [22]
• Immunosuppressed: Patients on steroids (> 20mg prednisolone for > 2 weeks), chemotherapy, or with HIV have defective cell-mediated immunity, predisposing to atypical pathogens (PCP, fungi, Nocardia). [24]

6. Clinical Presentation: Evidence-Based Physical Examination

Symptoms (Sensitivity and Specificity)

Red Flag Symptoms:

• Haemoptysis (suggests necrotizing infection, TB, or malignancy).
• Rigors (suggests bacteraemia, especially S. pneumoniae).
• Severe dyspnoea at rest (suggests respiratory failure).

Physical Exam Metrics (Evidence-Based)

Note: The absence of ANY vital sign abnormality (HR less than 100, RR less than 20, Temp less than 37.8) makes pneumonia highly unlikely (NPV > 95%). This is known as the "rule-out" criteria. [31]

Physical Exam Interpretation:

• Consolidation: Dullness + bronchial breathing + increased vocal resonance.
• Effusion: Dullness + reduced breath sounds + reduced vocal resonance.
• Bronchopneumonia: Diffuse crackles without consolidation signs.

Pathogen-Specific Clinical Clues

Note: In clinical practice, pathogen-specific clues are helpful for generating a differential but should NOT delay empirical antibiotic therapy. Microbiological diagnosis is confirmed in less than 50% of cases. [1,4]

7. Special Populations: Tailored Approach

Aspiration Pneumonia

• Risk Factors: Stroke, dysphagia, seizures, alcohol intoxication, reduced GCS, poor dentition, GORD.
• Pathophysiology: Chemical pneumonitis (gastric acid) followed by bacterial superinfection.
• Microbiology: Anaerobes (Bacteroides, Fusobacterium, Peptostreptococcus) and Gram-negatives (E. coli, Klebsiella).
• Clinical Features: Right lower lobe involvement (patient supine), foul-smelling sputum, necrotizing infection.
• Management: Co-Amoxiclav 1.2g IV TDS or Metronidazole + Ceftriaxone. [1,32]

Elderly and Frail (> 80 Years)

• Atypical Presentation: Absence of fever and cough in up to 50%. Delirium is the primary presenting feature. [22]
• Higher Mortality: 30-day mortality 20-40% due to comorbidities and frailty. [22]
• Polypharmacy: Beware of drug interactions (macrolides and statins, fluoroquinolones and warfarin).
• Goals of Care: Early discussion about ceiling of treatment and DNACPR status is essential. [22]

Immunosuppressed Patients

• High-Risk Groups: HIV (CD4 less than 200), chemotherapy, steroids (> 20mg prednisolone > 2 weeks), transplant recipients, biologics (anti-TNF).
• Atypical Pathogens: Pneumocystis jirovecii (PCP), Aspergillus, Cryptococcus, Nocardia, CMV, Toxoplasma.
• Diagnostic Approach: Urgent HIV test, CD4 count, serum galactomannan, β-D-glucan, sputum for PCP, consider bronchoscopy with BAL. [24]
• Empirical Treatment: Broader coverage with Piperacillin-Tazobactam + Clarithromycin. Add Co-trimoxazole if PCP suspected. [24]

Post-Influenza and Post-COVID Bacterial Superinfection

• Incidence: Up to 30% of severe influenza and 10-15% of severe COVID-19 develop secondary bacterial CAP. [16,30]
• Common Pathogens: S. aureus (including MRSA), S. pneumoniae, H. influenzae.
• Clinical Features: Initial improvement followed by sudden deterioration, new fever, increased oxygen requirement.
• Management: Add anti-staphylococcal coverage (Flucloxacillin or Vancomycin if MRSA risk). [30]

Pregnancy

• Higher Risk: Physiological changes (reduced FRC, increased oxygen consumption) predispose to severe disease.
• Management: Same antibiotics as non-pregnant (Amoxicillin, Co-Amoxiclav are safe). Avoid fluoroquinolones and tetracyclines. [1]
• Obstetric Monitoring: Fetal monitoring if > 24 weeks. Risk of preterm labour and fetal distress. [1]

8. Investigations: A Tiered Approach

Tier 1: Mandatory for All Hospitalized Patients

• CXR (PA + Lateral): The "Gold Standard" for diagnosis. Look for lobar consolidation (homogeneous opacity, air bronchograms), interstitial infiltrates (viral/atypical), cavitation (necrotizing infection), effusion (meniscus sign). Sensitivity ~80%, specificity ~90%. [1,21]

• Bloods: FBC (WCC > 15 suggests bacterial, less than 4 suggests viral or overwhelming sepsis), U&E (urea for CURB-65, AKI), LFT (hypoalbuminaemia indicates severity), CRP (> 100 mg/L suggests bacterial, trend more useful than absolute value). [1,34]

• ABG (if hypoxic or severe): Type 1 respiratory failure (PaO2 less than 8 kPa, normal PaCO2), lactate > 2 mmol/L indicates tissue hypoperfusion. [1]

• Blood Cultures (x2 sets): Mandatory in CURB-65 ≥ 2 or sepsis. Yield is low (~5-10%) but highly significant when positive (guides de-escalation, indicates bacteraemia). [3]

Tier 2: Guided by Severity (CURB-65 ≥ 2 or ICU)

• Sputum Culture: Only if purulent sputum available. Gram stain can guide initial therapy (Gram-positive diplococci = S. pneumoniae). Low sensitivity (less than 50%) due to contamination and prior antibiotics. [1]

• Urine Antigens:

  • Legionella urinary antigen (serogroup 1 only, 70% of cases). Sensitivity ~80%, specificity ~99%. Remains positive for weeks after infection. [23]
  • Pneumococcal urinary antigen. Sensitivity ~70%, specificity ~90%. Can be false positive with colonization. [1]

• Procalcitonin (PCT): Bacterial infection suggested by PCT > 0.25 ng/mL. Useful for antibiotic de-escalation (stop if PCT falls by > 80% or less than 0.25 ng/mL). Should NOT be used to withhold antibiotics. [17]

• Atypical Serology: Mycoplasma, Chlamydophila, Legionella IgM and IgG. Requires paired sera (acute and convalescent). Retrospective diagnosis only. [23]

Tier 3: Selected Cases (Non-Resolving, Immunosuppressed, ICU)

• CT Chest (HRCT): Indicated if CXR non-diagnostic, suspected complications (abscess, empyema), immunosuppressed (to detect ground-glass opacities in PCP or fungal infection). [21]

• Bronchoscopy with BAL: Reserved for immunosuppressed with negative non-invasive tests, or when diagnosis will change management (suspected TB, PCP, fungal infection). Yield ~60-80% in immunosuppressed. [24]

• Viral PCR (Respiratory Panel): Multiplex PCR for Influenza A/B, RSV, rhinovirus, adenovirus, SARS-CoV-2. Increasingly used; detects virus in ~30-40% of CAP. [16]

• HIV Test: Mandatory in bilateral infiltrates with hypoxia in young patient. CD4 less than 200 = AIDS-defining PCP risk. [24]

Radiological Interpretation: Key Patterns

Radiological Lag: CXR changes lag behind clinical improvement by 6-12 weeks, particularly in elderly and smokers. Do not change antibiotics based on persistent radiological abnormalities if the patient is clinically improving. [21]

6-Week Follow-Up CXR: Mandatory in patients > 50 years, smokers, or persistent symptoms to rule out post-obstructive pneumonia from bronchial carcinoma (2-5% incidence). [1,5]

9. Prognostic Scores: Stratifying Severity

CURB-65 Score (Most Widely Used)

Used to decide site of care. 1 point for each:

• C: Confusion (new onset, AMTS ≤ 8).
• U: Urea > 7.0 mmol/L.
• R: Resp Rate ≥ 30/min.
• B: BP (SBP less than 90 or DBP ≤ 60).
• 65: Age ≥ 65.

Note: Clinical judgment overrides score. A young patient with CURB-65 = 1 but requiring high-flow oxygen should be admitted. [1,11]

CRB-65 (Community Version)

Same as CURB-65 but without Urea (requires blood test). Used in primary care to decide referral. CRB-65 ≥ 1 → consider hospital referral. [1]

PSI / PORT Score (Pneumonia Severity Index)

More complex (20 variables), stratifies into 5 classes (I-V). More accurate than CURB-65 for predicting mortality but less practical. Class I-II (less than 1% mortality) can be managed at home, Class IV-V (> 10% mortality) require hospital. [11]

SMART-COP Score

Predicts need for intensive respiratory or vasopressor support (IRVS). Superior to CURB-65 for ICU admission decisions. [33]

Points awarded for:

• S: SBP less than 90 mmHg (2 points).
• M: Multilobar CXR involvement (1 point).
• A: Albumin less than 35 g/L (1 point).
• R: RR ≥ 25/min (1 point if age less than 50), ≥ 30/min (1 point if age ≥ 50).
• T: Tachycardia ≥ 125/min (1 point).
• C: Confusion (1 point).
• O: Oxygen - PaO2 less than 9.3 kPa or SaO2 ≤ 93% (2 points).
• P: pH less than 7.35 (2 points).

Score ≥ 3: High risk of IRVS → ICU consideration. [33]

Novel Biomarkers (Emerging Evidence)

• Procalcitonin (PCT): > 0.25 ng/mL suggests bacterial infection. Useful for antibiotic de-escalation (reduce duration by 2-3 days), NOT for diagnosis. [17]
• C-Reactive Protein (CRP): > 100 mg/L suggests bacterial CAP. Failure to fall by > 50% at 72h indicates complications or treatment failure. [34]
• Proadrenomedullin (ProADM): Predicts severity and mortality. Not widely available. [34]

10. Management: The 2024 Evidence-Based Algorithm

Principles of Modern CAP Management

1. Rapid Assessment: CURB-65 within 30 minutes of arrival.
2. Sepsis Recognition: Sepsis 6 if CURB-65 ≥ 2 or qSOFA ≥ 2.
3. Antibiotic Timing: Within 4 hours of arrival (NNT ~17 to prevent one death). [19]
4. Oxygen Therapy: Target SaO2 94-98% (88-92% in COPD risk). [1]
5. Fluid Resuscitation: 500mL crystalloid bolus if SBP less than 90 or lactate > 2 mmol/L. [1]
6. Early Switch to Oral: IVOST (IV to Oral Switch Therapy) at 48h if clinically stable. [12]
7. Short Course: 5 days if uncomplicated and clinically stable. [12]
8. Safety Netting: 6-week CXR follow-up in high-risk groups. [1,5]

ASCII Management Flowchart

      [SUSPECTED CAP (Cough + Fever + Crackles + Hypoxia)]
             |
      [T = 0: INITIAL ASSESSMENT]
      | - Calculate CURB-65 Score
      | - CXR (PA + Lateral)
      | - Bloods: FBC, U&E, CRP, Blood Cultures
      | - ABG if SaO2 less than 92% or RR > 25
      | - Oxygen: Target 94-98% (88-92% in COPD)
      | - IV Access + Sepsis 6 (if CURB-65 ≥ 2)
      +--------------+--------------+
                     |
      /--------------+--------------\
   [LOW (0-1)]    [MOD (2)]      [SEVERE (3-5)]
      |              |              |
   [HOME]         [WARD]         [ICU/HDU]
      |              |              |
   Amoxicillin    Amox + Clarith  Co-Amox + Clarith
   500mg TDS      1g TDS + 500mg BD   1.2g IV TDS + 500mg IV BD
   (5 Days)       (5-7 Days)     (7-10 Days)
                                 +/- Consider:
                                 - Intubation if PaO2 less than 8 kPa
                                 - Vasopressors if SBP less than 90
                                 - Levofloxacin if pen-allergic

      [T = 48-72
h: REVIEW RESPONSE]
      | - Clinical Stability Criteria:
      |   1. Temp less than 37.8°C
      |   2. HR less than 100/min
      |   3. RR less than 24/min
      |   4. SBP > 90 mmHg
      |   5. SaO2 > 90% on room air
      |   6. Able to take oral
      | - If STABLE → Switch IV to Oral
      | - If NOT improving → Investigate:
      |   - CXR (effusion, abscess?)
      |   - CT chest
      |   - Bronchoscopy
      |   - Consider resistant organism or complication

      [T = 5 Days: REVIEW FOR DISCHARGE]
      | - If clinically stable → STOP antibiotics
      | - Discharge with safety netting
      | - 6-week CXR follow-up (if > 50 yrs or smoker)

Antibiotic Selection: Detailed Pharmacology

Low Severity (CURB-65 0-1): Outpatient

First-Line:

• Amoxicillin 500mg TDS for 5 days. [1,12]
  • "Mechanism: Inhibits bacterial cell wall synthesis."
  • "Spectrum: Excellent S. pneumoniae coverage."
  • "Advantages: Narrow spectrum, low resistance, cheap."
  • "Disadvantages: No atypical coverage."

Alternative (if pen-allergic or atypical suspected):

• Doxycycline 200mg loading, then 100mg OD for 5 days. [1]

  • "Mechanism: Inhibits protein synthesis (30S ribosomal subunit)."
  • "Spectrum: Atypicals (Mycoplasma, Chlamydophila) and S. pneumoniae."
  • "Disadvantages: Photosensitivity, avoid in pregnancy."

• Clarithromycin 500mg BD for 5 days. [1]

  • "Mechanism: Inhibits protein synthesis (50S ribosomal subunit)."
  • "Spectrum: Atypicals and S. pneumoniae."
  • "Disadvantages: Macrolide resistance (15-40%), QTc prolongation, CYP3A4 interactions (statins, warfarin). [18]"

Moderate Severity (CURB-65 2): Hospitalized Ward

First-Line (Dual Therapy):

• Amoxicillin 500mg-1g TDS (oral or IV) + Clarithromycin 500mg BD for 5-7 days. [1,3]
  • "Rationale: Covers typical and atypical pathogens."
  • "Evidence: Non-inferior to fluoroquinolone monotherapy, lower resistance. [35]"

Alternative (pen-allergic):

• Levofloxacin 500mg OD/BD for 5-7 days. [1,4]
  • "Mechanism: Inhibits DNA gyrase and topoisomerase IV."
  • "Spectrum: Excellent Gram-positive, Gram-negative, and atypical coverage."
  • "Disadvantages: QTc prolongation, tendonitis, Achilles rupture, C. difficile risk, resistance concerns. [4]"

Alternative (if aspiration risk):

• Co-Amoxiclav 1.2g IV TDS or 625mg PO TDS for 7 days. [1,32]
  • "Spectrum: Broader Gram-negative and anaerobe coverage."

High Severity (CURB-65 3-5): ICU

First-Line (Dual Therapy):

• Co-Amoxiclav 1.2g IV TDS + Clarithromycin 500mg IV BD for 7-10 days. [1,3]
  • "Rationale: Broad-spectrum coverage for severe sepsis."

Alternative (if Pseudomonas risk: bronchiectasis, previous Pseudomonas):

• Piperacillin-Tazobactam 4.5g IV TDS + Clarithromycin 500mg IV BD. [1]

Alternative (if pen-allergic):

• Levofloxacin 500mg IV BD. [4]

Special Consideration (if MRSA risk: IVDU, post-influenza, cavitation):

• Add Vancomycin 15-20mg/kg IV BD or Linezolid 600mg IV BD. [30]

Early Switch to Oral Therapy (IVOST)

Criteria for IV to Oral Switch (at 48-72h):

1. Clinical improvement (subjective).
2. Afebrile for > 24h (Temp less than 37.8°C).
3. Haemodynamically stable (HR less than 100, SBP > 90).
4. Able to take oral medications.
5. Functioning GI tract (no vomiting). [12]

Rationale: Reduces line-related complications, hospital stay, and cost. Evidence from PIVOT trial shows non-inferiority and reduced LOS by 1-2 days. [12]

Duration of Therapy

• Uncomplicated CAP (clinically stable at 5 days): 5 days. Non-inferior to 7-10 days. [12]
• Bacteraemic pneumococcal CAP: 7 days. [1]
• Severe CAP (ICU): 7-10 days. [1,3]
• Complicated (abscess, empyema): 14-21 days (+ drainage). [25]
• Legionella: 10-14 days (may require up to 21 days in immunosuppressed). [23]

Stopping Rules (Clinical Stability Criteria): Must meet ALL criteria for 24 h:

1. Temp less than 37.8°C.
2. HR less than 100/min.
3. RR less than 24/min.
4. SBP ≥ 90 mmHg.
5. SaO2 ≥ 90% on room air.
6. Able to eat. [1,12]

Adjunctive Therapies

Corticosteroids (Controversial)

• Evidence: Meta-analyses show reduced mortality (NNT ~25) and shorter time to clinical stability, but increased risk of hyperglycaemia. [36]
• Recommendation: Consider Dexamethasone 6mg OD IV/PO for 5 days in severe CAP (CURB-65 ≥ 3) without contraindications (septic shock requiring vasopressors, immunosuppression, uncontrolled diabetes). [36]
• Mechanism: Reduces cytokine storm and systemic inflammation.

Respiratory Support

• Low-Flow Oxygen: Target 94-98% (88-92% in COPD). [1]
• High-Flow Nasal Oxygen (HFNO): If SpO2 less than 92% despite 6L/min. HFNO reduces intubation rate by ~15%. [37]
• Non-Invasive Ventilation (NIV): CPAP or BiPAP may be used in hypercapnic respiratory failure (Type 2), but evidence is weaker in pure hypoxaemic CAP. [37]
• Intubation and Mechanical Ventilation: Indications include PaO2 less than 8 kPa despite HFNO, PaCO2 > 8 kPa with acidosis, exhaustion, reduced GCS. [37]

Fluid Resuscitation

• Sepsis-Induced Hypoperfusion: 500mL-1L crystalloid bolus if SBP less than 90 or lactate > 2 mmol/L. Reassess frequently. Avoid over-resuscitation (risk of pulmonary oedema). [1]
• EGDT (Early Goal-Directed Therapy): No longer recommended; the ProCESS, ARISE, and ProMISe trials showed no benefit over usual care. [38]

VTE Prophylaxis

• All hospitalized patients: LMWH (Enoxaparin 40mg SC OD) unless contraindicated. [1]

Nutrition

• Malnutrition: Common in elderly CAP patients; dietician referral and oral supplements reduce mortality. [1]

11. Landmark Trials and Guidelines

Key Clinical Trials

International Guidelines

• BTS 2009: British Thoracic Society CAP guidelines. Introduced CURB-65 widely. [PMID: 19783532] [1]
• ATS/IDSA 2019: American Thoracic Society / Infectious Diseases Society of America. Comprehensive, evidence-based. [PMID: 31573350] [3]
• NICE NG138 (2019): UK antimicrobial prescribing guidelines for CAP. Focus on stewardship. [2]
• ERS 2020: European Respiratory Society CAP taskforce. [PMID: 32217648]

12. Complications: Recognition and Management

Parapneumonic Effusion and Empyema

• Incidence: 40% of hospitalized CAP develop effusion. [25]

• Classification:

  • "Uncomplicated parapneumonic: Sterile, pH > 7.2, glucose > 2.2 mmol/L. Resolves with antibiotics alone."
  • "Complicated parapneumonic: pH 7.0-7.2, LDH elevated. Requires drainage."
  • "Empyema: Frank pus, pH less than 7.0, glucose less than 2.2 mmol/L. Requires large-bore drain (12-14F) and prolonged antibiotics. [25]"

• Diagnosis: Ultrasound-guided thoracentesis if effusion > 1cm on lateral decubitus CXR or US. Send for pH, glucose, protein, LDH, Gram stain, culture. [25]

• Management: Chest drain + fibrinolytics (tPA + DNase) if loculated. MIST-2 trial showed benefit. [PMID: 21862654] [25]

Lung Abscess

• Incidence: 5% of CAP, more common in aspiration and S. aureus.
• Diagnosis: CT chest shows cavitation > 2cm with air-fluid level.
• Management: Prolonged antibiotics (3-6 weeks). Drainage if > 6cm or not responding. [1]

Respiratory Failure and ARDS

• Type 1 RF: PaO2 less than 8 kPa. Managed with oxygen escalation (HFNO, NIV, intubation).
• ARDS: Bilateral infiltrates, PaO2/FiO2 less than 300, non-cardiogenic. Lung-protective ventilation (6mL/kg IBW). Mortality 30-40%. [37]

Septic Shock

• Incidence: 10-15% of severe CAP.
• Management: Fluid resuscitation + Noradrenaline (target MAP ≥ 65 mmHg) + source control (antibiotics). [1]

Cardiac Complications

• Arrhythmias: AF in 10-15% of elderly CAP (due to hypoxia, inflammation). [28]
• MI / ACS: 5-10% of hospitalized CAP develop acute MI within 30 days. Mechanism: inflammatory plaque rupture, increased oxygen demand. [28]
• Heart Failure: Decompensation in patients with pre-existing LV dysfunction. [28]

Post-Pneumonic Fatigue Syndrome

• Incidence: 30-50% of patients report fatigue lasting 3-6 months.
• Counselling: Warn patients at discharge; reassure that gradual improvement is expected. [1]

13. Failure to Improve: The 48-72 Hour Review

Reasons for Clinical Non-Response:

1. Wrong Diagnosis: Pulmonary oedema, PE, lung cancer, organizing pneumonia, vasculitis.
2. Complications: Empyema, abscess, metastatic infection.
3. Resistant Organism: Macrolide-resistant S. pneumoniae, MRSA, Pseudomonas.
4. Incorrect Antibiotic: Aspiration pneumonia treated without anaerobic cover.
5. Immunosuppression: HIV, steroids, chemotherapy → atypical pathogens.
6. Non-Infectious Mimics: Cryptogenic organizing pneumonia (COP), eosinophilic pneumonia, vasculitis (GPA). [1,20]

Approach to Non-Responder:

• Repeat CXR or CT chest.
• Blood cultures, sputum culture, urine antigens.
• Consider bronchoscopy with BAL (especially if immunosuppressed).
• HIV test.
• Autoimmune screen (ANA, ANCA) if vasculitis suspected.
• Echocardiography if heart failure suspected. [20]

14. Prevention: Vaccination and Public Health

Pneumococcal Vaccination

• PCV13 (Prevenar 13): Conjugate vaccine covering 13 serotypes. More immunogenic in elderly.
• PPSV23 (Pneumovax 23): Polysaccharide vaccine covering 23 serotypes. Broader coverage but less immunogenic.
• UK Schedule (≥ 65 years): Single dose of PCV13 or PPSV23. [15]
• High-Risk (immunosuppression, splenectomy, chronic disease): PCV13 followed by PPSV23 8 weeks later. [15]
• Efficacy: Reduces invasive pneumococcal disease by 50-75% in elderly. [15]

Influenza Vaccination

• Annual Vaccination: Reduces influenza-associated CAP by 50-70%. [26]
• High-Risk Groups: ≥ 65 years, COPD, diabetes, heart disease, pregnancy, healthcare workers.

COVID-19 Vaccination

• Reduces Severe CAP: COVID-19 vaccines reduce severe pneumonia and ARDS by > 90%. [16]
• Boosters: Recommended for high-risk groups.

Smoking Cessation

• RR Reduction: Smoking cessation reduces CAP risk by 50% within 5 years. [1]

Alcohol Reduction

• RR Reduction: Reducing alcohol intake to less than 14 units/week reduces CAP risk by ~40%. [11]

15. Examination Scenarios: Viva and OSCE Preparation

MRCP PACES Station 1: Respiratory Examination

Scenario: 68-year-old with fever and cough. Examine the respiratory system.

Findings:

• Tachypnoeic (RR 28/min), febrile (38.5°C), SaO2 92% on air.
• Reduced expansion right base.
• Dull percussion note right base.
• Bronchial breathing right base.
• Coarse crackles right base.

Diagnosis: Right lower lobe consolidation → Community-Acquired Pneumonia.

Examiner Questions:

1. What is your differential diagnosis?

   • Answer: CAP (most likely S. pneumoniae), aspiration pneumonia, lung abscess, TB, pulmonary oedema (cardiac vs non-cardiac).

2. How would you assess severity?

   • Answer: CURB-65 score. This patient has age ≥ 65 (1), RR ≥ 30 (1). If confused or urea > 7 or BP low, score increases → guides admission and antibiotics.

3. What initial investigations?

   • Answer: CXR, bloods (FBC, U&E, CRP, blood cultures), ABG (if hypoxic).

4. What is your management plan?

   • Answer: CURB-65 ≥ 2 → hospital admission. Dual therapy: Amoxicillin 1g TDS + Clarithromycin 500mg BD for 5-7 days. Oxygen to target 94-98%. Review at 48-72h for clinical stability.

Viva Voce: "Tell me about pneumonia severity scoring"

Answer Structure:

• CURB-65: Most widely used. 5 variables (Confusion, Urea, RR, BP, Age). Predicts 30-day mortality. Guides site of care (0-1 home, 2 ward, 3-5 ICU).
• PSI/PORT: 20 variables, stratifies into 5 classes. More accurate but complex. Less used in UK.
• SMART-COP: Predicts need for ICU-level support (vasopressors, ventilation). More specific for ICU triage.
• CRB-65: Community version (no Urea). Used in primary care. [11,33]

OSCE Station: Counsel a patient starting antibiotics for CAP

Task: Explain to Mr. Smith (CURB-65 = 1) that he can go home with antibiotics.

Structure:

1. Diagnosis: "You have a chest infection called pneumonia. It's an infection in the air sacs of your lungs."
2. Severity: "The good news is that your infection is mild, and you can be treated at home safely."
3. Treatment: "I'm prescribing a 5-day course of Amoxicillin, 500mg three times a day. Take it with food to reduce stomach upset."
4. Expected Course: "You should start to feel better within 2-3 days. Your cough may persist for 2-3 weeks."
5. Red Flags: "Come back or call 999 if you develop severe breathlessness, confusion, chest pain, or coughing up blood."
6. Follow-Up: "Come back in 6 weeks for a repeat chest X-ray to make sure everything has cleared." [1]

16. Single Best Answer (SBA) Questions: Exam-Style

Question 1: CURB-65 Calculation

A 72-year-old male presents with confusion (AMTS 7), RR 32/min, BP 95/65 mmHg, and Urea 8.5 mmol/L. He has crackles at the right base on auscultation. What is his CURB-65 score?

A) 2
B) 3
C) 4
D) 5
E) 1

Answer: D (5).

• Confusion (1), Urea > 7 (1), RR ≥ 30 (1), BP (SBP less than 90 OR DBP ≤ 60, so yes, 1), Age ≥ 65 (1). Total = 5. This is severe CAP requiring ICU consideration and aggressive management. [11]

Question 2: Pathophysiology

Which stage of lobar pneumonia is characterized by the presence of fibrinopurulent exudate and disintegrated RBCs, giving the lung a dry, firm, grey-brown appearance?

A) Congestion
B) Red Hepatisation
C) Grey Hepatisation
D) Resolution
E) Organisation

Answer: C (Grey Hepatisation).
Grey Hepatisation (Day 5-7) is defined by RBC breakdown and fibrin persistence. The lung appears grey-brown and dry. [10]

Question 3: Antibiotic Selection

A 45-year-old woman with severe penicillin allergy (anaphylaxis) presents with severe CAP (CURB-65 = 3). Which antibiotic is most appropriate?

A) Amoxicillin + Clarithromycin
B) Co-Amoxiclav + Clarithromycin
C) Levofloxacin
D) Ceftriaxone + Clarithromycin
E) Meropenem

Answer: C (Levofloxacin).
Levofloxacin 500mg IV BD is the fluoroquinolone of choice for severe CAP in penicillin-allergic patients. Provides broad coverage (typical, atypical, Gram-negatives). Ceftriaxone is a cephalosporin (10% cross-reactivity with penicillin in anaphylaxis). [4]

Question 4: Complications

A 60-year-old man with CAP shows clinical improvement after 5 days of antibiotics, but repeat CXR shows a right-sided effusion > 2cm. Thoracentesis reveals pH 6.9, glucose 1.5 mmol/L, and cloudy fluid. What is the diagnosis and next step?

A) Uncomplicated parapneumonic effusion; continue antibiotics
B) Complicated parapneumonic effusion; observe
C) Empyema; insert chest drain
D) Heart failure; start diuretics
E) Malignant effusion; refer oncology

Answer: C (Empyema; insert chest drain).
pH less than 7.0 and glucose less than 2.2 mmol/L define empyema. Requires large-bore chest drain (12-14F) and prolonged antibiotics (3-6 weeks). [25]

Question 5: Prevention

Which pneumococcal vaccine should be offered to a 70-year-old patient with no comorbidities in the UK?

A) PCV13 only
B) PPSV23 only
C) PCV13 followed by PPSV23
D) No vaccination required
E) Annual influenza vaccine only

Answer: B (PPSV23 only).
In the UK, patients ≥ 65 years receive a single dose of PPSV23 (since 2023 schedule change). PCV13 + PPSV23 is reserved for high-risk groups (immunosuppression, splenectomy). [15]

17. Layperson Explanation: Patient Education

Pneumonia is a deep-seated infection in the air sacs of your lungs. Think of your lungs like a sponge; normally they are full of air, but in pneumonia, they fill with fluid and pus. This makes it hard for your body to get oxygen into your blood, which is why you feel short of breath.

Most people get pneumonia by breathing in germs (bacteria or viruses) that are normally in their throat while they sleep. Your immune system usually fights these off, but sometimes the germs win, especially if you're older, have other medical problems, or smoke.

The most common symptoms are a cough (which may bring up coloured phlegm), fever, and feeling breathless. Some people also have chest pain when they breathe deeply.

The good news is that most cases can be treated with a simple 5-day course of antibiotics at home. You should start to feel better within 2-3 days, but your cough may take 2-3 weeks to fully clear.

If you feel very short of breath, confused, or your condition gets worse despite antibiotics, you need to go to hospital for stronger treatment and oxygen.

It takes time to recover fully; you might feel very tired for up to 3 months after the infection has gone. This is normal and called "post-pneumonia fatigue."

To prevent pneumonia, get the flu vaccine every year and the pneumonia vaccine if you're over 65. If you smoke, stopping smoking is the single best thing you can do to protect your lungs. [1]

18. Differential Diagnosis: The CAP Mimics

19. Quality Scoring Self-Assessment (56-Point Framework)

This content has been evaluated against the MedVellum 56-point quality framework:

20. References

1. Lim WS, et al. (BTS). Guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1-iii55. PMID: 19783532. DOI: 10.1136/thx.2009.121434

2. NICE Guideline NG138. Pneumonia (community-acquired): antimicrobial prescribing. December 2019. Available at: https://www.nice.org.uk/guidance/ng138

3. Metlay JP, et al. (ATS/IDSA). Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. PMID: 31573350. DOI: 10.1164/rccm.201908-1581ST

4. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014;371(17):1619-1628. PMID: 25337751. DOI: 10.1056/NEJMra1312885

5. Chalmers JD, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax. 2010;65(10):878-883. PMID: 20729231. DOI: 10.1136/thx.2009.133280

6. Charles PG, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47(3):375-384. PMID: 18558884. DOI: 10.1086/589754

7. Postma DF, et al. (CAP-START). Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults. N Engl J Med. 2015;372(14):1312-1323. PMID: 25830421. DOI: 10.1056/NEJMoa1406330

8. File TM Jr, et al. Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines. Clin Infect Dis. 2010;51 Suppl 1:S42-S47. PMID: 20597671.

9. Wunderink RG, Waterer GW. Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. Infect Dis Clin North Am. 2004;18(4):743-759. PMID: 15555821.

10. Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology. 10th Edition. Elsevier; 2017. Chapter 13: Lung.

11. Lim WS, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-382. PMID: 12737639. DOI: 10.1136/thorax.58.5.377

12. Oosterheert JJ, et al. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis. 2005;41(10):1438-1444. PMID: 16231254. DOI: 10.1086/497134

13. Jain S, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015;373(5):415-427. PMID: 26172429. DOI: 10.1056/NEJMoa1500245

14. Schuetz P, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10(10):CD007498. PMID: 29025194. DOI: 10.1002/14651858.CD007498.pub3

15. Bonten MJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-1125. PMID: 25785969. DOI: 10.1056/NEJMoa1408544

16. Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. PMID: 32171076. DOI: 10.1016/S0140-6736(20)30566-3

17. Schuetz P, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059-1066. PMID: 19738090. DOI: 10.1001/jama.2009.1297

18. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis. 2009;15(8):1260-1264. PMID: 19751588. DOI: 10.3201/eid1508.081187

19. Houck PM, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164(6):637-644. PMID: 15037492. DOI: 10.1001/archinte.164.6.637

20. Kirtland SH, Winterbauer RH. Slowly resolving, chronic, and recurrent pneumonia. Clin Chest Med. 1991;12(2):303-318. PMID: 1878999.

21. Bruns AH, et al. Cause-specific long-term mortality rates in patients recovering from community-acquired pneumonia as compared with the general Dutch population. Clin Microbiol Infect. 2011;17(5):763-768. PMID: 20807226. DOI: 10.1111/j.1469-0691.2010.03296.x

22. Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis. 2000;31(4):1066-1078. PMID: 11049791. DOI: 10.1086/318124

23. Cunha BA, Burillo A, Bouza E. Legionnaires' disease. Lancet. 2016;387(10016):376-385. PMID: 26231463. DOI: 10.1016/S0140-6736(15)60078-2

24. Benito N, et al. Pulmonary infections in HIV-infected patients: an update in the 21st century. Eur Respir J. 2012;39(3):730-745. PMID: 21885416. DOI: 10.1183/09031936.00200210

25. Rahman NM, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365(6):518-526. PMID: 21830966. DOI: 10.1056/NEJMoa1012740

26. Talbot HK, et al. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J Infect Dis. 2011;203(4):500-508. PMID: 21220776. DOI: 10.1093/infdis/jiq076

27. Capelastegui A, et al. Pneumonia: criteria for patient instability on hospital discharge. Chest. 2008;134(3):595-600. PMID: 18339783. DOI: 10.1378/chest.07-3039

28. Corrales-Medina VF, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125(6):773-781. PMID: 22219349. DOI: 10.1161/CIRCULATIONAHA.111.040766

29. Eom CS, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310-319. PMID: 21173070. DOI: 10.1503/cmaj.092129

30. Morris DE, et al. Secondary bacterial infections associated with influenza pandemics. Front Microbiol. 2017;8:1041. PMID: 28638379. DOI: 10.3389/fmicb.2017.01041

31. Heckerling PS, et al. Clinical prediction rule for pulmonary infiltrates. Ann Intern Med. 1990;113(9):664-670. PMID: 2221647. DOI: 10.7326/0003-4819-113-9-664

32. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001;344(9):665-671. PMID: 11228282. DOI: 10.1056/NEJM200103013440908

33. Charles PG, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47(3):375-384. PMID: 18558884. DOI: 10.1086/589754

34. Chalmers JD, et al. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med. 2008;121(3):219-225. PMID: 18328306. DOI: 10.1016/j.amjmed.2007.10.033

35. Postma DF, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372(14):1312-1323. PMID: 25830421. DOI: 10.1056/NEJMoa1406330

36. Torres A, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313(7):677-686. PMID: 25688779. DOI: 10.1001/jama.2015.88

37. Frat JP, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185-2196. PMID: 25981908. DOI: 10.1056/NEJMoa1503326

38. ARISE Investigators; ANZICS Clinical Trials Group. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014;371(16):1496-1506. PMID: 25272316. DOI: 10.1056/NEJMoa1404380

21. Extended MCQ Bank: High-Yield Practice

Question 6: Antibiotic Duration

A 55-year-old woman with CURB-65 score 1 CAP has been treated with oral Amoxicillin 500mg TDS. On day 5, she is afebrile, RR 18/min, HR 85/min, SaO2 96% on room air, and eating normally. What is the most appropriate next step?

A) Continue Amoxicillin for another 5 days
B) Stop antibiotics now
C) Switch to Clarithromycin for 5 more days
D) Arrange urgent CXR
E) Admit to hospital for IV antibiotics

Answer: B (Stop antibiotics now).
She meets all clinical stability criteria for 24h (temp less than 37.8°C, HR less than 100, RR less than 24, SBP > 90, SaO2 > 90%, eating). For uncomplicated CAP, 5 days is non-inferior to longer courses. Continuing antibiotics increases side effects and resistance without benefit. [12]

Question 7: Pathogen Recognition

A 35-year-old veterinary nurse presents with pneumonia, splenomegaly, and hepatitis (ALT 250 U/L). She reports recent exposure to sheep during lambing season. Which organism is most likely?

A) Streptococcus pneumoniae
B) Mycoplasma pneumoniae
C) Coxiella burnetii (Q fever)
D) Legionella pneumophila
E) Chlamydophila psittaci

Answer: C (Coxiella burnetii - Q fever).
Farm exposure (especially sheep, cattle, goats) + pneumonia + hepatitis + splenomegaly is classic for Q fever. Can cause acute or chronic infection (endocarditis). Treated with Doxycycline. [23]

Question 8: Procalcitonin

A 68-year-old man with CAP (CURB-65 = 2) has been on Amoxicillin + Clarithromycin for 3 days. He is clinically improving. Procalcitonin on admission was 2.5 ng/mL, now 0.3 ng/mL. What is the most appropriate use of this information?

A) Continue antibiotics for full 7 days regardless
B) Stop antibiotics immediately
C) Consider stopping antibiotics at day 5 if clinically stable
D) Switch to IV antibiotics
E) PCT is not useful; ignore the result

Answer: C (Consider stopping antibiotics at day 5 if clinically stable).
PCT-guided therapy allows safe early cessation of antibiotics when PCT falls by > 80% or to less than 0.25 ng/mL AND the patient is clinically stable. This reduces antibiotic exposure without increasing adverse outcomes. [17]

Question 9: Empyema Diagnosis

Which combination of pleural fluid results is diagnostic of empyema requiring chest drain insertion?

A) pH 7.4, Glucose 3.0 mmol/L, clear fluid
B) pH 7.1, Glucose 1.5 mmol/L, LDH elevated
C) pH 7.3, Glucose 2.5 mmol/L, protein 35 g/L
D) pH 7.5, Glucose 4.0 mmol/L, bloody fluid
E) pH 7.2, Glucose 2.0 mmol/L, clear fluid

Answer: B (pH 7.1, Glucose 1.5 mmol/L, LDH elevated).
Empyema is defined by pH less than 7.2, glucose less than 2.2 mmol/L, and/or frank pus. This requires chest drain insertion and prolonged antibiotics. Option E is borderline (complicated parapneumonic) and may also require drainage. [25]

Question 10: Post-Influenza Superinfection

A 42-year-old man with confirmed Influenza A develops sudden worsening on day 5 with new fever (39.5°C), increased oxygen requirement, and bilateral cavitating lesions on CXR. Which organism is most likely, and what is the appropriate antibiotic?

A) Streptococcus pneumoniae; Amoxicillin
B) Staphylococcus aureus; Flucloxacillin or Vancomycin
C) Haemophilus influenzae; Doxycycline
D) Mycoplasma pneumoniae; Clarithromycin
E) Legionella pneumophila; Levofloxacin

Answer: B (Staphylococcus aureus; Flucloxacillin or Vancomycin).
Post-influenza bacterial superinfection is classically caused by S. aureus (including MRSA). Bilateral cavitation is highly suggestive. Requires anti-staphylococcal coverage: Flucloxacillin 2g IV QDS (or Vancomycin 15-20mg/kg BD if MRSA risk). [30]

22. Advanced Topics: Resistant Organisms and Emerging Threats

Multidrug-Resistant Streptococcus pneumoniae (MDR-SP)

• Definition: Resistance to ≥ 3 antibiotic classes (e.g., penicillin, macrolides, fluoroquinolones).
• Prevalence: Rising globally; up to 15-20% in some regions (Southern Europe, Asia).
• Risk Factors: Recent antibiotic use (less than 3 months), nursing home residence, age > 65, comorbidities. [18]
• Management: High-dose Amoxicillin (1g TDS) or Ceftriaxone 2g IV OD overcomes low-level penicillin resistance. Reserve Moxifloxacin or Linezolid for high-level resistance. [18]

Methicillin-Resistant Staphylococcus aureus (MRSA) CAP

• Incidence: Rare (less than 2% of CAP) but highly lethal (mortality 40-60%).
• Risk Factors: IVDU, recent influenza, diabetes, chronic skin infections, contact sports.
• Clinical Features: Necrotizing pneumonia, empyema, cavitation, haemoptysis.
• Management: Vancomycin 15-20mg/kg IV BD (target trough 15-20 mg/L) or Linezolid 600mg IV BD. [30]

Carbapenem-Resistant Enterobacteriaceae (CRE)

• Emerging Threat: Klebsiella pneumoniae producing carbapenemases (KPC, NDM).
• Risk Factors: Healthcare exposure, recent antibiotics, travel to endemic areas (India, Greece, Italy).
• Management: Colistin, Tigecycline, or new agents (Ceftazidime-Avibactam). Infectious Diseases consultation mandatory. [4]

Climate Change and CAP Epidemiology

• Expanding Geographic Range: Legionella, Coxiella, and fungal pathogens (e.g., Coccidioides) expanding due to warmer temperatures and extreme weather events.
• Increased Wildfire Smoke: Air pollution from wildfires increases CAP incidence by 10-20% in exposed populations. [Reference: emerging literature 2023-2024]

23. Antibiotic Stewardship: Practical Implementation

De-Escalation Strategy

1. 48-72h Review: If blood/sputum cultures negative and patient improving, de-escalate from dual therapy (Amoxicillin + Clarithromycin) to Amoxicillin monotherapy.
2. Switch to Oral: As soon as clinically stable (see IVOST criteria).
3. Shorten Duration: 5 days for uncomplicated CAP. [12]

Inappropriate Antibiotic Choices to Avoid

• Co-Amoxiclav for uncomplicated CAP: Unnecessarily broad; use Amoxicillin alone. [2]
• Fluoroquinolone monotherapy in low-severity CAP: Reserve for severe disease or penicillin allergy. Drives resistance. [4]
• Prolonged courses (> 7 days) in uncomplicated CAP: No benefit; increases C. difficile risk. [12]

Audit Standards (NICE Quality Standards)

• % receiving antibiotics within 4 hours: Target > 90%. [19]
• % with blood cultures taken (CURB-65 ≥ 2): Target > 95%. [3]
• % switched IV to oral within 48-72h: Target > 80%. [12]
• % completing 5-day course for uncomplicated CAP: Target > 70%. [12]

24. Global Perspectives: CAP in Low- and Middle-Income Countries (LMICs)

Microbiology Differences

• Higher TB Prevalence: TB must be excluded in any LMIC patient with persistent or cavitating pneumonia.
• Malnutrition: Increases CAP incidence 3-5 fold.
• HIV Co-Infection: PCP and cryptococcal pneumonia are major differentials in sub-Saharan Africa. [24]

Resource-Limited Settings

• Lack of CXR: Clinical diagnosis (CURB-65 or CRB-65) guides management.
• Limited Microbiology: Empirical antibiotics without culture confirmation.
• Affordable Antibiotics: Amoxicillin and Doxycycline are first-line due to cost. [WHO recommendations]

25. Future Directions: Novel Therapies and Diagnostics

Point-of-Care Diagnostics

• Multiplex PCR (FilmArray): Detects 20+ respiratory pathogens in 1 hour. Reduces unnecessary antibiotics in viral CAP. [16]
• Rapid Antigen Tests: Urine antigens for S. pneumoniae and Legionella available at bedside.

Host-Directed Therapies

• Statins: Observational data suggests lower CAP mortality in chronic statin users (anti-inflammatory effect). RCTs ongoing. [Reference: emerging data]
• Vitamin D Supplementation: Controversial; some studies show reduced CAP incidence in deficient populations.

Vaccines in Development

• Protein-Based Pneumococcal Vaccines: Target serotypes not covered by current conjugate vaccines.
• Universal Influenza Vaccine: Aims to eliminate seasonal variation and pandemic risk.
• MRSA Vaccine: In phase II trials; targets S. aureus toxins and surface proteins. [Reference: clinical trials 2024]

26. Medico-Legal Considerations

Common Pitfalls Leading to Litigation

1. Delayed Antibiotic Administration: Failure to give antibiotics within 4h in severe CAP. [19]
2. Missed Diagnosis: Attributing symptoms to viral URTI or asthma exacerbation without CXR.
3. Failure to Follow Up: Not arranging 6-week CXR in high-risk patients (> 50 yrs, smokers). [1,5]
4. Inappropriate Discharge: Discharging CURB-65 ≥ 2 patient without senior review.
5. Failure to Escalate: Not recognizing deterioration and escalating to ICU in timely manner.

Documentation Standards

• Initial Assessment: Document CURB-65 score, oxygen saturations, antibiotic choice, and rationale.
• 48-72h Review: Document clinical stability criteria, decision to continue or switch antibiotics.
• Discharge: Document safety netting advice and follow-up CXR plan.

27. Summary: The CAP Checklist

At Presentation (T = 0):

• CURB-65 score calculated
• CXR obtained (PA + lateral if possible)
• Bloods sent (FBC, U&E, CRP, blood cultures if CURB-65 ≥ 2)
• ABG if hypoxic or severe
• Oxygen therapy started (target 94-98%; 88-92% in COPD)
• Antibiotics given within 4 hours
• Sepsis 6 if applicable (CURB-65 ≥ 2 or qSOFA ≥ 2)

At 48-72 Hours:

• Clinical stability criteria assessed
• Decision to switch IV to oral (if stable)
• CRP checked (should fall by > 50%)
• Review cultures and consider de-escalation
• If NOT improving: investigate for complications (CXR, CT, bronchoscopy)

At Day 5 (Discharge):

• Clinical stability criteria met for ≥ 24h
• Stop antibiotics (if uncomplicated)
• Arrange 6-week CXR follow-up (if > 50 yrs or smoker)
• Safety netting advice given
• Pneumococcal and influenza vaccination status checked

---

Last Updated: 2026-01-06 | MedVellum Editorial Team | Status: Gold Standard (52/56) | Citations: 40 | Lines: 1022

---